Filters

Search for: [Abstract = "Background. The aim of the study was to compare efficacy and tolerance of first\-line palliative chemotherapy EOX \(epirubicin\/oxaliplatin\/capecitabine\) and mDCF \(docetaxel\/cisplatin\/5FU\/leucovorin\) regimens in patients with locally advanced inoperable or metastatic gastric or gastroesophageal junction adenocarcinoma without overexpression of HER2 receptors.Methods. Each chemotherapy regimen was assigned with 21 patients. Planned treatment consisted of 12 every\-two\-weeks mDCF cycles or 8 every\-three\-weeks EOX cycles \(24 weeks of treatment in each arm\). The primary endpoint was overall survival in all patients who commenced at least one chemotherapy cycle.Results. Median progression\-free survival was 5.8 months in EOX group and 7.5 months in mDCF group \(p=0,11\), and median overall survival was 8.5 months and 12.0 months respectively \(p=0,219\). In the EOX arm there were more frequent reductions of cytostatics doses \(p=0,009\) as well as delays in the administration of subsequent chemotherapy cycles \(p=0,424\). Rates of all grade 3 or 4 adverse events were comparable between both arms \(p=1,000\), however nausea \(p=0,093\), thromboembolic events \(p=0,663\) and grade 3 or 4 neutropenia \(p=0,443\) were more frequent in the EOX group.Conclusions. In patients with locally advanced inoperable or metastatic gastric or gastroesophageal junction adenocarcinoma without overexpression of HER2 receptors treatment with mDCF regimen is associated with a statistically non\-significant 3.5 month longer median overall survival without increase in toxicity."]

Number of results: 1

items per page

This page uses 'cookies'. More information